GLP-1–albumin fusion protein
Albiglutide
Albiglutide is a fusion protein incorporating a GLP-1 analog dimer and human albumin. Pharmacokinetic and pharmacodynamic studies characterize it. Its architecture differs from acylated peptides that associate with albumin available in the environment.
This is a research reference, not a product offered in the Pureza catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.
Mechanism described in the literature
The construct was designed as a DPP-4-resistant GLP-1 mimetic genetically fused to albumin. Resistance and fusion are different features and should not be merged into one explanation of persistence.
Other names in the literature
- Albiglutide
Albumin incorporated into the construct
The experimental description identifies a genetic fusion, not a physical mixture of albumin and peptide or solely reversible albumin binding. Findings for another GLP-1–albumin construct require architectural comparison before it can be treated as equivalent to albiglutide.
Exposure and response measured separately
The 2008 study examined albiglutide concentrations and glucose variables in participants with type 2 diabetes. A complementary study compared exposure conditions. Pharmacokinetic and pharmacodynamic curves distinguish how much material was detected from what biological variable was observed over follow-up.
Population also changes interpretation
The 2009 investigation characterized albiglutide in volunteers without diabetes, recording exposure, time to maximum concentration, terminal half-life and follow-up variables. Comparing it with 2008 requires preserving each population and design. They are not one sample, and half-life does not automatically determine every outcome's duration.
Questions and answers
Are albiglutide and an albumin-bound peptide equivalent?
No. Albumin is part of a defined fusion construct in albiglutide.
Did both cited studies examine the same population?
No. One examined participants with type 2 diabetes and the other volunteers without diabetes.
Sources
- Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. — J Clin Endocrinol Metab, 2008
- Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.
- Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. — Diabetes Obes Metab, 2009
- Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects.